Clostridium difficile is the cause of significant morbidity, mortality and cost. Systemic and mucosal immunity to C. difficile toxin A has been associated with protection from clinical disease, amelioration of clinical symptoms, and prevention of relapse. The previous funding period of this grant resulted in several advances in the use of live, oral, attenuated Vibrio cholerae as a vector for immunizing against heterologous antigens. The long term goal of the next, proposed segment of funding is to develop and test in animals a V. cholerae-based vector vaccine that will stimulate systemic and mucosal humoral immunity against toxin A of C. difficile, and that is appropriate for ultimate human use. The current proposal has FOUR SPECIFIC AIMS to achieve this long term goal.
These aims are: 1. To develop and analyze in vitro an anti-C. difficile V. cholerae-based vaccine vector. A glutamine auxotroph of V. cholerae vaccine strain CVD 103-HgR (a safe and immunogenic vaccine strain in North American human volunteer studies) will be engineered to express toxin A-HlyA (a fusion protein between a non-toxic 720 amino acid C. difficile toxin A fragment and the E. coli hemolysin A secretion signal) from plasmids of various copy numbers that complement the glutamine auxotrophy. The vaccine vector strains will also express HlyBD (the pore-forming proteins that mediate extracellular secretion of toxin A-HlyA), and an immunoadjuvant molecule, such as LT(R192G) (a non-toxic derivative of Escherichia coli heat-labile enterotoxin that retains immunoadjuvancy). Expression and cellular localization of toxin A-HlyA and LT(R192G) will be evaluated, as well as viability and stability of the vaccines in vitro. 2. The viability, stability, immunogenicity, and reactogenicity of the various oral vaccine constructs will then be evaluated in mice. 3. A combination oral priming and transcutaneous boosting immunization strategy (the latter with C. difficile toxin A toxoid with or without an immunoadjuvant) will be evaluated in mice for production of both mucosal and systemic immunity to toxin A. 4. The immunogenicity, reactogenicity, and protective efficacy of the most promising vaccine strategy will be assessed in rabbits, the latter will be measured using a challenge assay in which purified C. difficile toxin A is injected into ligated ileal loops of vaccinated and control animals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI040725-06A1
Application #
6544664
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Taylor, Katherine A
Project Start
1996-12-01
Project End
2007-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
6
Fiscal Year
2002
Total Cost
$411,377
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Rychert, Jenna; Creely, David; Mayo-Smith, Leslie M et al. (2015) Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Vibrio cholerae. J Clin Microbiol 53:329-31
Khan, Ashraful I; Chowdhury, Fahima; Harris, Jason B et al. (2010) Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1. Scand J Infect Dis 42:48-56
Harris, Jason B; Podolsky, Michael J; Bhuiyan, Taufiqur R et al. (2009) Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl Trop Dis 3:e403
Rollenhagen, Julianne E; Kalsy, Anuj; Saksena, Rina et al. (2009) Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine 27:4917-22
Chowdhury, Fahima; Khan, Ashraful I; Harris, Jason B et al. (2008) A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 27:986-92
Harris, Aaron M; Chowdhury, Fahima; Begum, Yasmin Ara et al. (2008) Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. Am J Trop Med Hyg 79:708-14
Jayasekera, Channa R; Harris, Jason B; Bhuiyan, Saruar et al. (2008) Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis 198:1055-61
LaRocque, Regina C; Krastins, Bryan; Harris, Jason B et al. (2008) Proteomic analysis of Vibrio cholerae in human stool. Infect Immun 76:4145-51
Harris, Jason B; LaRocque, Regina C; Chowdhury, Fahima et al. (2008) Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2:e221
Ghose, Chandrabali; Kalsy, Anuj; Sheikh, Alaullah et al. (2007) Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 75:2826-32

Showing the most recent 10 out of 40 publications